Hypomagnesemia is common among patients with cancer, and can lead to increased morbidity and mortality as well as discontinuation of potentially life-saving treatments. Hypomagnesemia may occur due to transcellular shifts, decreased intake, gastrointestinal losses, or following treatment with cisplatin, monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), anti-EGFR tyrosine kinase inhibitors (TKIs) and anti-human epidermal growth factor receptor 2 (HER-2) mAbs [1].
